WO2006020994A3 - Compositions and methods using hyaluronic acid and hyluronidase inhibitors - Google Patents

Compositions and methods using hyaluronic acid and hyluronidase inhibitors Download PDF

Info

Publication number
WO2006020994A3
WO2006020994A3 PCT/US2005/029177 US2005029177W WO2006020994A3 WO 2006020994 A3 WO2006020994 A3 WO 2006020994A3 US 2005029177 W US2005029177 W US 2005029177W WO 2006020994 A3 WO2006020994 A3 WO 2006020994A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyaluronic acid
compositions
methods
hyluronidase
inhibitors
Prior art date
Application number
PCT/US2005/029177
Other languages
French (fr)
Other versions
WO2006020994A2 (en
Inventor
William L Hunter
David M Gravett
Philip M Toleikis
John K Jackson
Original Assignee
Angiotech Int Ag
Univ British Columbia
William L Hunter
David M Gravett
Philip M Toleikis
John K Jackson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiotech Int Ag, Univ British Columbia, William L Hunter, David M Gravett, Philip M Toleikis, John K Jackson filed Critical Angiotech Int Ag
Priority to JP2007525883A priority Critical patent/JP2008509935A/en
Priority to EP05786742A priority patent/EP1781305A2/en
Priority to CA002577022A priority patent/CA2577022A1/en
Priority to AU2005272578A priority patent/AU2005272578A1/en
Priority to BRPI0515191-0A priority patent/BRPI0515191A/en
Publication of WO2006020994A2 publication Critical patent/WO2006020994A2/en
Publication of WO2006020994A3 publication Critical patent/WO2006020994A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Compositions and devices including hyaluronic acid and a compound that inhibits degradation of hyaluronic acid, and methods of making and using same.
PCT/US2005/029177 2004-08-13 2005-08-15 Compositions and methods using hyaluronic acid and hyluronidase inhibitors WO2006020994A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2007525883A JP2008509935A (en) 2004-08-13 2005-08-15 Compositions and methods using hyaluronic acid and hyaluronic acid inhibitors
EP05786742A EP1781305A2 (en) 2004-08-13 2005-08-15 Compositions and methods using hyaluronic acid and hyaluronidase inhibitors
CA002577022A CA2577022A1 (en) 2004-08-13 2005-08-15 Compositions and methods using hyaluronic acid and hyluronidase inhibitors
AU2005272578A AU2005272578A1 (en) 2004-08-13 2005-08-15 Compositions and methods using hyaluronic acid and hyluronidase inhibitors
BRPI0515191-0A BRPI0515191A (en) 2004-08-13 2005-08-15 pharmaceutical composition, method for augmenting bone or replacing bone loss, method for reducing pain associated with postoperative scarring, method for preventing surgical adhesion, method for enlarging or repairing skin or tissue, method for maintaining eye fluid volume during eye surgery , method for reducing pain associated with osteoarthritis, method for treating gastroesophageal reflux disease, method for treating or preventing urinary incontinence, method for treating or preventing fecal incontinence, implant method and medical device

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US60121804P 2004-08-13 2004-08-13
US60121404P 2004-08-13 2004-08-13
US60/601,218 2004-08-13
US60/601,214 2004-08-13

Publications (2)

Publication Number Publication Date
WO2006020994A2 WO2006020994A2 (en) 2006-02-23
WO2006020994A3 true WO2006020994A3 (en) 2006-07-20

Family

ID=35355711

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/029177 WO2006020994A2 (en) 2004-08-13 2005-08-15 Compositions and methods using hyaluronic acid and hyluronidase inhibitors

Country Status (7)

Country Link
US (1) US20060040894A1 (en)
EP (1) EP1781305A2 (en)
JP (1) JP2008509935A (en)
AU (1) AU2005272578A1 (en)
BR (1) BRPI0515191A (en)
CA (1) CA2577022A1 (en)
WO (1) WO2006020994A2 (en)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8138265B2 (en) * 2003-01-10 2012-03-20 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
US8137688B2 (en) * 2003-01-10 2012-03-20 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
US7465766B2 (en) * 2004-01-08 2008-12-16 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
FR2861734B1 (en) 2003-04-10 2006-04-14 Corneal Ind CROSSLINKING OF LOW AND HIGH MOLECULAR MASS POLYSACCHARIDES; PREPARATION OF INJECTABLE SINGLE PHASE HYDROGELS; POLYSACCHARIDES AND HYDROGELS OBTAINED
US8802651B2 (en) * 2004-06-30 2014-08-12 Abbott Medical Optics Inc. Hyaluronic acid in the enhancement of lens regeneration
WO2006032144A1 (en) * 2004-09-23 2006-03-30 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions or inflammatory disease using fucans from various echinoderm sources
ITPD20040312A1 (en) * 2004-12-15 2005-03-15 Fidia Advanced Biopolymers Srl PROSTHESIS AND SUPPORT FOR REPLACEMENT, REPAIR, REGENERATION OF THE MENISCUS
SI2664334T1 (en) * 2004-12-30 2015-06-30 Genzyme Corporation Regimens for intra-articular viscosupplementation
EP2068864B1 (en) * 2006-04-26 2017-08-23 The Regents of the University of California Therapeutic uses of urolithins
EP3009477B1 (en) 2006-07-20 2024-01-24 Orbusneich Medical Pte. Ltd Bioabsorbable polymeric composition for a medical device
US20080082170A1 (en) * 2006-09-29 2008-04-03 Peterman Marc M Apparatus and methods for surgical repair
EP2073754A4 (en) 2006-10-20 2012-09-26 Orbusneich Medical Inc Bioabsorbable polymeric composition and medical device background
US7959942B2 (en) 2006-10-20 2011-06-14 Orbusneich Medical, Inc. Bioabsorbable medical device with coating
DE102007003765A1 (en) * 2007-01-19 2008-07-24 Farco-Pharma Gmbh Pharmaceutical composition for the treatment of incontinence
US8343536B2 (en) 2007-01-25 2013-01-01 Cook Biotech Incorporated Biofilm-inhibiting medical products
KR20090114427A (en) * 2007-01-31 2009-11-03 바이오액티브스, 인코포레이티드 Methods of reducing 15-F2t-IsoP levels in mammals
WO2008094697A2 (en) * 2007-02-01 2008-08-07 The Trustees Of The University Of Pennsylvania Disc augmentation with hyaluronic acid
WO2008139123A2 (en) * 2007-05-11 2008-11-20 Galderma Research & Development Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same
EP2155212A2 (en) * 2007-05-11 2010-02-24 Galderma Research & Development Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same
US20080293637A1 (en) * 2007-05-23 2008-11-27 Allergan, Inc. Cross-linked collagen and uses thereof
DE102007028360B4 (en) 2007-06-15 2016-04-14 Marcus Asam Combination of active ingredients for cosmetic preparations
FR2918276B1 (en) * 2007-07-02 2010-01-22 Anteis Sa "USE OF A NATURAL POLYSACCHARIDE (S) GEL FOR THE PREPARATION OF AN INJECTION FORMULATION FOR THE TREATMENT OF JOINT DEGENERESCENCES"
US8318695B2 (en) * 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
FR2919999B1 (en) * 2007-08-13 2010-01-29 Oreal HYALURONIC ACID COMPOSITIONS
EP2033689A1 (en) * 2007-08-22 2009-03-11 Italfarmacia S.r.l. Injectable dermatological composition for treatment of the wrinkles
US8697044B2 (en) 2007-10-09 2014-04-15 Allergan, Inc. Crossed-linked hyaluronic acid and collagen and uses thereof
WO2009055610A1 (en) * 2007-10-26 2009-04-30 Cytori Therapeutics, Inc. Syringe system for controlled delivery or removal of material
WO2009065116A1 (en) 2007-11-16 2009-05-22 Aspect Pharmaceuticals Llc Compositions and methods for treating purpura
US8394784B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
US20090143348A1 (en) * 2007-11-30 2009-06-04 Ahmet Tezel Polysaccharide gel compositions and methods for sustained delivery of drugs
US8394782B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having increased longevity
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
EP2249891B1 (en) * 2008-02-13 2016-05-25 The Cleveland Clinic Foundation Molecular enhancement of extracellular matrix and methods of use
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
EP2698173A1 (en) * 2008-02-29 2014-02-19 Coloplast A/S Compositions and methods for augmentation and regeneration of living tissue in a subject
US8410180B2 (en) * 2008-04-30 2013-04-02 The Cleveland Clinic Foundation Methods to treat urinary incontinence
US8652506B2 (en) * 2008-06-05 2014-02-18 Boston Scientific Scimed, Inc. Bio-degradable block co-polymers for controlled release
ITMC20080129A1 (en) * 2008-07-08 2008-10-07 Phitogen Holding S P A SYNTHESIS OF RETICULATED HYALURONIC ACID WITH INHIBITOR OF IALURONIDASI MICROINCAPSULATO.
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
DE102008038368A1 (en) * 2008-08-19 2010-02-25 Biotronik Vi Patent Ag Use of organic gold complexes as bioactive and radioopaque stent coating for permanent and degradable vascular implants
EP2324064B1 (en) 2008-09-02 2017-11-08 Tautona Group LP Threads of hyaluronic acid and/or derivatives thereof, methods of making thereof and uses thereof
US9072791B2 (en) * 2008-09-30 2015-07-07 Denki Kagaku Kogyo Kabushiki Kaisha Photostabilized pharmaceutical compositions
US8263069B2 (en) * 2008-12-31 2012-09-11 Johnson Lanny L Compositions including anthocyanin or anthocyanidin for the prevention or treatment of articular cartilage-associated conditions
JP4900848B2 (en) * 2009-01-26 2012-03-21 宏美 林 Artificial joint
ITMI20090240A1 (en) * 2009-02-20 2010-08-21 O T I S R L Officine Terapie Inno Vative COMPOSITION INCLUDING FOREIGN CAFFEIC ACID FOR THE INHIBITION OF HUMAN ENZYME IALURONIDASIS
US8979821B2 (en) 2009-04-14 2015-03-17 Fezza Family Properties, Llc Lacrimal filler
EP2435045A2 (en) * 2009-05-29 2012-04-04 Symatese Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
US20110070204A1 (en) * 2009-09-22 2011-03-24 Ilan Elias Medium for handling and storing biological tissues of the musculoskeletal system outside an organism
WO2011049629A2 (en) 2009-10-22 2011-04-28 Api Genesis, Llc Methods of making and using compositions comprising flavonoids
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US20110172180A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US20110171310A1 (en) * 2010-01-13 2011-07-14 Allergan Industrie, Sas Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
US20110171286A1 (en) * 2010-01-13 2011-07-14 Allergan, Inc. Hyaluronic acid compositions for dermatological use
AU2015234293B2 (en) * 2010-01-13 2017-04-27 Allergan Industrie Sas Stable hydrogel compositions including additives
WO2011109130A1 (en) * 2010-03-01 2011-09-09 Tautona Group Lp Threads of hyaluronic acid and methods of use thereof
WO2011109129A1 (en) * 2010-03-01 2011-09-09 Tautona Group Lp Threads of cross-linked hyaluronic acid and methods of use thereof
AU2010348090B2 (en) * 2010-03-12 2015-09-03 Allergan Industrie Sas A fluid composition comprising a hyaluronan polymer and mannitol for improving skin condition
ES2729994T3 (en) * 2010-03-22 2019-11-07 Allergan Inc Crosslinked polysaccharide and protein polysaccharide hydrogels for soft tissue augmentation
GB2480295A (en) * 2010-05-12 2011-11-16 Alan John Waddon Polymeric aqueous composition
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8889123B2 (en) 2010-08-19 2014-11-18 Allergan, Inc. Compositions and soft tissue replacement methods
US8883139B2 (en) 2010-08-19 2014-11-11 Allergan Inc. Compositions and soft tissue replacement methods
US9005605B2 (en) 2010-08-19 2015-04-14 Allergan, Inc. Compositions and soft tissue replacement methods
JP5824455B2 (en) * 2010-08-23 2015-11-25 デンカ株式会社 Crosslinked hyaluronic acid composition and self-crosslinked hyaluronic acid particles
US8455436B2 (en) * 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US20130096081A1 (en) 2011-06-03 2013-04-18 Allergan, Inc. Dermal filler compositions
CN103702659B (en) 2011-06-03 2016-12-21 阿勒根公司 Dermal filler composition including antioxidant
US9393263B2 (en) 2011-06-03 2016-07-19 Allergan, Inc. Dermal filler compositions including antioxidants
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
US8623839B2 (en) 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
US9662422B2 (en) 2011-09-06 2017-05-30 Allergan, Inc. Crosslinked hyaluronic acid-collagen gels for improving tissue graft viability and soft tissue augmentation
US20130244943A1 (en) 2011-09-06 2013-09-19 Allergan, Inc. Hyaluronic acid-collagen matrices for dermal filling and volumizing applications
ITAN20110138A1 (en) 2011-10-12 2012-01-11 Regenyal Lab S R L SYNTHESIS OF A MULTIFASIC INJECTABLE GEL BASED ON FREE AND RETICULATED MONOFASIC HYALURONIC ACID AND BIPHASIC HYALURONIC ACID ASSOCIATED WITH HYDROXYAPATITIS WITH INHIBITOR OF IALURONIDASE MICROINCAPSULATE.
JP5772678B2 (en) * 2012-03-26 2015-09-02 国立大学法人北見工業大学 Cosmetic and functional food materials with water retention, water absorption and hyaluronidase inhibitory activity
CN103421064A (en) * 2012-05-21 2013-12-04 中国医学科学院药物研究所 Two metabolites of anti-cerebral-apoplexy medicine pinocembrin and synthetic methods of the two metabolites
FR2991876B1 (en) * 2012-06-13 2014-11-21 Vivacy Lab COMPOSITION, IN AQUEOUS MEDIUM, COMPRISING AT LEAST ONE HYALURONIC ACID AND AT LEAST ONE WATER-SOLUBLE SALT OF SUCROSE OCTASULFATE
US20140005142A1 (en) * 2012-06-28 2014-01-02 Howard Franklin Method of stably treating incontinence using a bulking agent
WO2014056723A1 (en) * 2012-10-08 2014-04-17 Anteis S.A. Injectable sterile aqueous formulation based on crosslinked hyaluronic acid and on hydroxyapatite, for therapeutic use
CN102973495A (en) * 2012-11-15 2013-03-20 上海景峰制药股份有限公司 Method of slowing down degradation of sodium hyaluronate in body
ITMI20130075A1 (en) * 2013-01-21 2014-07-22 Altergon Sa ORAL COMBINATION FOR THE PREVENTION AND TREATMENT OF BRAIN, PELVIC AND URO-GENITAL PATHOLOGIES
KR102016745B1 (en) * 2013-02-01 2019-09-02 아이진 주식회사 Compositions for reducing or inhibiting the formation of scar comprising BMP-7 and excipients
US9205105B2 (en) * 2013-05-22 2015-12-08 John Ascencion Campa, Iii Indication and technique for the use of cross-linked hyaluronic acid in the management of pain
WO2015018461A1 (en) * 2013-08-09 2015-02-12 Genbiotech Therapeutic compositions comprising hyaluronic acid
US9968623B2 (en) 2013-08-29 2018-05-15 Lanny Leo Johnson Prepackaged sterile syringe or containers with various substance concentrations with or without bioactive reagent
FR3014694B1 (en) * 2013-12-13 2016-11-11 Roquette Freres METHYL-CYCLODEXTRIN-BASED COMPOSITIONS FOR THE TREATMENT AND / OR PREVENTION OF DISEASES BY INCREASING THE CHOLESTEROL-HDL RATE
FR3020570B1 (en) * 2014-04-30 2017-07-21 Pierre Fabre Dermo-Cosmetique ASSOCIATION OF A HYALURONIC ACID AND A SULFATE POLYSACCHARIDE
US9655998B2 (en) 2014-08-07 2017-05-23 Cook Medical Technologies Llc Encapsulated drug compositions and methods of use thereof
US11241520B2 (en) 2014-08-07 2022-02-08 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US9180226B1 (en) 2014-08-07 2015-11-10 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US10722444B2 (en) 2014-09-30 2020-07-28 Allergan Industrie, Sas Stable hydrogel compositions including additives
US9295752B1 (en) 2014-09-30 2016-03-29 Covidien Lp Bioadhesive for occluding vessels
MX2017009241A (en) 2015-01-16 2018-03-23 Spineovations Inc Method of treating spinal disk.
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
WO2016128783A1 (en) 2015-02-09 2016-08-18 Allergan Industrie Sas Compositions and methods for improving skin appearance
TW202114648A (en) * 2015-03-06 2021-04-16 日商參天製藥股份有限公司 Ophthalmic composition
KR101731865B1 (en) 2015-03-19 2017-05-02 전북대학교산학협력단 Tissue engineering biodegradable polymer scaffold and a method for manufacturing it
JP2017014154A (en) * 2015-07-01 2017-01-19 公立大学法人岡山県立大学 Hyaluronic acid production promoter containing urolithins
WO2017027177A1 (en) 2015-08-08 2017-02-16 Chl Industries, Llc Improved hyaluronan and modified-hyaluronan in biomedical applications
WO2017057504A1 (en) 2015-09-30 2017-04-06 学校法人自治医科大学 Viscoelastic composition
ES2621877B1 (en) * 2016-01-04 2018-05-04 Agencia Pública Empresarial Sanitaria Hospital De Poniente SOLUTION FOR ENDOSCOPIC RESECTION
EP3210572A1 (en) 2016-02-29 2017-08-30 Elodie Jane Siney Intraocular lens comprising drug-containing microspheres
AU2017241516B2 (en) * 2016-04-01 2021-03-11 Boston Scientific Scimed, Inc. Injectable compositions and methods of preparation and use thereof
WO2018020501A1 (en) * 2016-07-27 2018-02-01 Marbelle Threads Ltd. Threads of cross-linked hyaluronic acid and hydroxyapatite
IT201600088648A1 (en) * 2016-08-31 2018-03-03 Alpiflor S R L Nutritional or pharmaceutical composition and food supplement containing said nutritional or pharmaceutical composition
IT201600121617A1 (en) * 2016-11-30 2018-05-30 Nekkar Lab Srl COMPOSITION FOR THE TREATMENT OF GASTROESOFAGEO REFLUX
IT201700124434A1 (en) * 2017-10-31 2019-05-01 Sofar Swiss Sa Tablet to suck and / or dissolve in the mouth based on hyaluronic acid and chondroitin sulfate and their salts for use in the treatment of a subpopulation of GERD patients.
CA3088552C (en) * 2018-02-09 2023-09-26 Boston Scientific Scimed, Inc. Gel compositions and methods of preparation and use thereof
JP2021155334A (en) * 2018-05-01 2021-10-07 学校法人近畿大学 Pharmaceutical composition containing middle-molecular-weight heparin or amino acid derivatives of middle-molecular-weight heparin
JP6621558B2 (en) 2018-05-28 2019-12-18 花王株式会社 Preventive or ameliorating agent for nocturia
US11660373B2 (en) * 2019-02-09 2023-05-30 Tetrous, Inc. Demineralized bone fiber implant compositions and methods for rotator cuff and ACL repair
KR102321658B1 (en) * 2019-12-06 2021-11-03 영산대학교산학협력단 Implant surface coating composition comprising rosmarinus officinalis extract
KR102344959B1 (en) * 2019-12-06 2021-12-28 영산대학교산학협력단 Composition for improving osteointegration of implants comprising rosmarinus officinalis extract
CN111012953B (en) * 2019-12-10 2022-03-29 华熙生物科技股份有限公司 Preparation method of enzymolysis-resistant cross-linked hyaluronic acid gel, obtained product and application
EP3854377A1 (en) * 2020-01-22 2021-07-28 Laboratoires Genevrier Sas Composition comprising hyaluronic acid and a polyol or carboxymethylcellulose
IT202000022477A1 (en) * 2020-09-23 2022-03-23 Sofar Swiss Sa COMPOSITIONS INCLUDING A PLANT CHONDROITIN OR AN ANALOGUE THEREOF AND THEIR USE IN THE TREATMENT OF DISORDERS OF THE MUCOSA OF THE ORAL TRACT, PHARYNGO-LARYNGEAL AND/OR GASTRO-ESOPHAGEAL
CN114699554A (en) * 2021-12-20 2022-07-05 南京思元医疗技术有限公司 Injection for correcting skin wrinkles for medical cosmetology and preparation method thereof
US20230381012A1 (en) * 2022-05-31 2023-11-30 Max Azevedo System and Method for Fallopian Birth Control
CN115252893B (en) * 2022-08-26 2023-04-25 上海市第十人民医院 Preparation of anti-inflammatory and antioxidant nerve conduit
CN115487171A (en) * 2022-11-10 2022-12-20 郑州大学 Hyaluronic acid-isoliquiritigenin conjugate, dissolving type microneedle patch, preparation method and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440427B1 (en) * 1991-06-17 2002-08-27 Biovitrum Ab Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer
WO2003000191A2 (en) * 2001-06-25 2003-01-03 Depuy Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438253A (en) * 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
JPS60100516A (en) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd Preparation of sustained release microcapsule
GB8504025D0 (en) * 1985-02-16 1985-03-20 Biopharm Ltd Hyaluronidase
US4746504A (en) * 1986-03-14 1988-05-24 Bio-Technology General Corp. Heavy metal salts of hyaluronic acid and their use as antimicrobial agents
US5916880A (en) * 1987-12-21 1999-06-29 Bukh Meditec A/S Reduction of skin wrinkling using sulphated sugars
JP2670680B2 (en) * 1988-02-24 1997-10-29 株式会社ビーエムジー Polylactic acid microspheres containing physiologically active substance and method for producing the same
US5527779A (en) * 1988-03-23 1996-06-18 Top Gold Pty Limited Topically applied gold organic complex
US5356883A (en) * 1989-08-01 1994-10-18 Research Foundation Of State University Of N.Y. Water-insoluble derivatives of hyaluronic acid and their methods of preparation and use
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5910489A (en) * 1990-09-18 1999-06-08 Hyal Pharmaceutical Corporation Topical composition containing hyaluronic acid and NSAIDS
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
US5358883A (en) * 1992-02-03 1994-10-25 Motorola, Inc. Lateral bipolar transistor
US6218373B1 (en) * 1992-02-20 2001-04-17 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US5942498A (en) * 1992-02-20 1999-08-24 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
US6114314A (en) * 1992-02-21 2000-09-05 Hyal Pharmaceutical Corp. Formulations containing hyaluronic acid
US6214331B1 (en) * 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
US5612321A (en) * 1995-06-22 1997-03-18 Hercules Incorporated Antioxidant grafted polysaccharides
US5665428A (en) * 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
PT876165E (en) * 1995-12-18 2006-10-31 Angiotech Biomaterials Corp COMPOSITIONS OF RETICULATED POLYMERS AND PROCESSES FOR THEIR USE
US6632457B1 (en) * 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
CA2365767A1 (en) * 1999-03-15 2000-09-21 Trustees Of Boston University Angiogenesis inhibition
US20040043047A1 (en) * 1999-03-26 2004-03-04 Parfums Christian Dior Cosmetic or dermatological compositions containing at least one substance for increasing the functionality and/or expression of the CD44 membrane receptors of skin cells
US6312725B1 (en) * 1999-04-16 2001-11-06 Cohesion Technologies, Inc. Rapid gelling biocompatible polymer composition
BR0112109A (en) * 2000-06-29 2007-05-29 Biosyntech Canada Inc composition and method for the correction and regeneration of cartilage and other tissues
ATE392907T1 (en) * 2000-07-28 2008-05-15 Anika Therapeutics Inc BIOABSORBABLE COMPOSITE MATERIALS MADE OF DERIVATIZED HYALURONIC ACID
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
CA2451245A1 (en) * 2001-06-25 2003-01-03 Depuy International Limited Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints
EP1465596A1 (en) * 2002-01-18 2004-10-13 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs
ITPD20020064A1 (en) * 2002-03-12 2003-09-12 Fidia Advanced Biopolymers Srl FOREIGN DERIVATIVES OF HYALURONIC ACID FOR THE PREPARATION OF HYDROGELD FOR USE IN THE BIOMEDICAL, SANITARY AND SURGICAL FIELD AND AS A SYSTEM
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US6682904B1 (en) * 2002-08-15 2004-01-27 Deliatroph Pharmaceuticals, Inc. Specific inhibitors of hyaluronidase 2, and methods of identifying and using same
EP1682196A2 (en) * 2003-11-10 2006-07-26 Angiotech International Ag Medical implants and anti-scarring agents
AU2004293463A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Implantable sensors and implantable pumps and anti-scarring agents
US20050209664A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Electrical devices and anti-scarring agents
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440427B1 (en) * 1991-06-17 2002-08-27 Biovitrum Ab Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer
WO2003000191A2 (en) * 2001-06-25 2003-01-03 Depuy Composition comprising glycosaminogycans and hyaluronidase inhibitors for the treatment of arthritic joints

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BURKHARDT D ET AL: "INHIBITION OF SYNOVIAL FLUID LYSOSOMAL GLYCOSIDASES BY ANTI-ARTHRITIC GOLD PREPARATIONS", AGENTS AND ACTIONS, BIRKHAEUSER VERLAG, BASEL, CH, vol. 8, no. 3, 1978, pages 251 - 257, XP009045785, ISSN: 0065-4299 *

Also Published As

Publication number Publication date
BRPI0515191A (en) 2008-07-08
CA2577022A1 (en) 2006-02-23
JP2008509935A (en) 2008-04-03
US20060040894A1 (en) 2006-02-23
WO2006020994A2 (en) 2006-02-23
AU2005272578A1 (en) 2006-02-23
EP1781305A2 (en) 2007-05-09

Similar Documents

Publication Publication Date Title
WO2006020994A3 (en) Compositions and methods using hyaluronic acid and hyluronidase inhibitors
WO2005117870A3 (en) Combination of proton pump inhibitor, buffering agent, and prokinetic agent
WO2006071762A3 (en) Pyrimidine-based inhibitors of dipeptidyl peptidase iv and methods
TW200735865A (en) Compositions of an anticonvulsant and methods of using the same for reversing weight gain
WO2009082701A8 (en) Hcv protease inhibitors and uses thereof
WO2007098352A3 (en) Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors
WO2008060622A3 (en) Improved methods and compositions for wound healing
AU2003241464A1 (en) Compositions and methods using proton pump inhibitors
WO2006007448A3 (en) Pharmaceutical co-crystal compositions and related methods of use
WO2006023651A3 (en) Extended treatment of multiple sclerosis
WO2007067836A3 (en) Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors
WO2007019439A3 (en) Block copolymer compositions and uses thereof
WO2005117872A3 (en) Dual acting snri-nmda antagonists for the treatment of genitourinary disorders
WO2006034035A3 (en) Treatment of ischemia
WO2007144779A3 (en) Compositions comprising porphyra and methods of making and using thereof
WO2007095258A3 (en) Rhamnolipid compositions and related methods of use
TW200621160A (en) Anti-termite agent
WO2010066639A3 (en) Skin lightening compositions with acetylcholinesterase inhibitors
WO2006029398A3 (en) All-trans-retinol : all-trans-13,14-dihydroretinol saturase and methods of its use
WO2006036817A3 (en) Fungal variants and uses thereof
WO2006069159A3 (en) Pharmaceutical compositions comprising amorphous benzimidazole compounds
WO2006078998A3 (en) Methods and compositions for decreasing saliva production
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
WO2004112771A8 (en) Pharmaceutical compositions including an antihistamine and a stimulant and use thereof
WO2007021879A3 (en) Production of l-ribose and other rare sugars

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007525883

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2577022

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005272578

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005272578

Country of ref document: AU

Date of ref document: 20050815

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2005786742

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005272578

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580035142.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005786742

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0515191

Country of ref document: BR